| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jens Juul Holst | Q28373106 |
| P2093 | author name string | J J Holst | |
| P2860 | cites work | Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo | Q27999767 |
| Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum | Q28117412 | ||
| Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes | Q28260260 | ||
| Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats | Q28574165 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. | Q32085854 | ||
| Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes | Q33209301 | ||
| Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas | Q34234727 | ||
| Complete sequences of glucagon-like peptide-1 from human and pig small intestine | Q34678376 | ||
| Exon duplication and divergence in the human preproglucagon gene | Q34713786 | ||
| Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides | Q34713867 | ||
| GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. | Q35098054 | ||
| Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance | Q35144434 | ||
| Incretins, insulin secretion and Type 2 diabetes mellitus | Q35669308 | ||
| Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system | Q35714885 | ||
| Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. | Q35809679 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| MK-431 (Merck). | Q36130013 | ||
| Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem | Q36276495 | ||
| Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans | Q37377728 | ||
| Induction of intestinal epithelial proliferation by glucagon-like peptide 2. | Q37449481 | ||
| Immunoreactive gastric inhibitory polypeptide | Q39642179 | ||
| The brain-gut-skin triangle: New peptides | Q40103530 | ||
| Glucagon-like peptide-1 prevents beta cell glucolipotoxicity | Q40565084 | ||
| Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas | Q40920945 | ||
| The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients | Q40922729 | ||
| Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity | Q41051549 | ||
| Glicentin is present in the pig pancreas | Q41494363 | ||
| Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. | Q41527377 | ||
| Evidence that glicentin contains the entire sequence of glucagon | Q41824006 | ||
| Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin | Q41877635 | ||
| Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. | Q42435174 | ||
| Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats | Q42519283 | ||
| Glucagon-like peptide-1 7-36: a physiological incretin in man. | Q43623564 | ||
| Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats | Q43631722 | ||
| Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers | Q43638669 | ||
| Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4 | Q43684539 | ||
| Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment | Q43687918 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats | Q43972544 | ||
| Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes | Q43972608 | ||
| Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice | Q43973972 | ||
| Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity | Q44015997 | ||
| Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity | Q44016001 | ||
| Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects | Q44273278 | ||
| Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes | Q44599736 | ||
| Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells | Q44777018 | ||
| One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. | Q44865459 | ||
| Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial | Q44909518 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. | Q45257473 | ||
| Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus | Q45306841 | ||
| Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom | Q46167760 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes | Q46484235 | ||
| Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). | Q46502032 | ||
| Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs | Q46875376 | ||
| Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. | Q46946154 | ||
| Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas | Q47234077 | ||
| Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. | Q48053907 | ||
| Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. | Q48218648 | ||
| Hamster preproglucagon contains the sequence of glucagon and two related peptides | Q48398917 | ||
| Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. | Q51244259 | ||
| Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. | Q51521725 | ||
| Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. | Q51578359 | ||
| Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. | Q51584065 | ||
| Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 | ||
| Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. | Q51601217 | ||
| Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects | Q51606971 | ||
| Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential | Q58448872 | ||
| Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig | Q58449056 | ||
| Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects | Q58449089 | ||
| GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans | Q58449333 | ||
| Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut | Q58449388 | ||
| Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas* | Q58449399 | ||
| Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours | Q58449457 | ||
| Relationship of glicentin to proglucagon and glucagon in the porcine pancreas | Q58449525 | ||
| GUT GLUCAGON AND REACTIVE HYPOGLYCÆMIA | Q58449585 | ||
| INCREASED GUT GLUCAGON RELEASE AS PATHOGENETIC FACTOR IN REACTIVE HYPOGLYCqMIA? | Q58449586 | ||
| Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39) amide, a specific exendin rec | Q67681211 | ||
| Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing | Q68895656 | ||
| Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8 | Q69522651 | ||
| Stimulation of insulin secretion by gastric inhibitory polypeptide in man | Q69602585 | ||
| Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption | Q70275008 | ||
| Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Isolation of the peptide | Q70511800 | ||
| Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats | Q71444770 | ||
| Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV | Q71940328 | ||
| Gastric inhibitory polypeptide | Q72765686 | ||
| Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells | Q73224788 | ||
| PROMOTION OF INSULIN SECRETION BY GLUCAGON | Q78559101 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 253-260 | |
| P577 | publication date | 2006-01-14 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005 | |
| P478 | volume | 49 |
| Q80426417 | ADOPT: lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy |
| Q48722095 | Activation of Nesfatin-1-Containing Neurones in the Hypothalamus and Brainstem by Peripheral Administration of Anorectic Hormones and Suppression of Feeding via Central Nesfatin-1 in Rats |
| Q46943450 | Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance |
| Q36640590 | Are sulfonylureas passé? |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q37677036 | Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus |
| Q37974632 | Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults |
| Q37950344 | Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1. |
| Q46707968 | Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. |
| Q36975470 | Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice |
| Q38253931 | Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy |
| Q38665753 | Controlled release of biologics for the treatment of type 2 diabetes |
| Q40104293 | Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line |
| Q33415965 | Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris |
| Q37930945 | Diabetes remission after bariatric surgery: is it just the incretins? |
| Q36834433 | Diabetes: advances in treatment |
| Q34589793 | Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. |
| Q36783164 | Dipeptidyl peptidase-4: a key player in chronic liver disease |
| Q58572799 | Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1 |
| Q27026687 | Do we really know why diabetes remits after gastric bypass surgery? |
| Q36753691 | Drug-induced endocrine and metabolic disorders |
| Q33743998 | Effect of gastric bypass surgery on the incretins |
| Q47158959 | Effects of activated carbon N-acetylcysteine sustained-release microcapsule on dipeptidyl peptidase IV expression in young rats with non-alcoholic fatty liver disease |
| Q36882784 | Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans |
| Q28088578 | Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus |
| Q33741938 | Evaluation of intragastric vs intraperitoneal glucose tolerance tests in the evaluation of insulin resistance in a rodent model of burn injury and glucagon-like polypeptide-1 treatment |
| Q35748345 | Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy |
| Q37049686 | Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity |
| Q53964243 | Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. |
| Q37066877 | Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver |
| Q37412024 | Exercise therapy in type 2 diabetes |
| Q64084791 | From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy |
| Q38055195 | GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. |
| Q39168828 | GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro |
| Q38089183 | GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity |
| Q24653673 | GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity |
| Q55657669 | Glycosaminoglycan Conjugation for Improving the Duration of Therapeutic Action of Glucagon-Like Peptide-1. |
| Q37990142 | Gut feelings about diabetes |
| Q28081671 | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide |
| Q37021310 | History of current non-insulin medications for diabetes mellitus |
| Q36756533 | Human adenovirus type 36 enhances glucose uptake in diabetic and nondiabetic human skeletal muscle cells independent of insulin signaling |
| Q33610842 | Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines |
| Q46494673 | Incretin and islet hormonal responses to fat and protein ingestion in healthy men. |
| Q58447924 | Incretin based therapies: do they hold their promise? |
| Q37345249 | Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes |
| Q34699191 | Incretin-based therapies in prediabetes: Current evidence and future perspectives |
| Q36580608 | Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes |
| Q36860616 | Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease? |
| Q33785308 | Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. |
| Q35939660 | Liraglutide for treating type 1 diabetes |
| Q37874613 | Liraglutide for type 2 diabetes mellitus |
| Q37778209 | Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus |
| Q36678584 | Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? |
| Q37288741 | New drugs for type 2 diabetes mellitus: what is their place in therapy? |
| Q26823824 | New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin |
| Q37606024 | New therapies for diabesity. |
| Q51478679 | Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. |
| Q36672151 | PACAP Inhibits β-cell Mass Expansion in a Mouse Model of Type II Diabetes: Persistent Suppressive Effects on Islet Density |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q35832189 | Pharmacological management of metabolic syndrome and its lipid complications |
| Q36793605 | Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents |
| Q37221770 | Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes |
| Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
| Q26784039 | Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy |
| Q39636280 | Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway |
| Q55364507 | SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. |
| Q47114286 | Semaglutide seems to be more effective the other GLP-1Ras |
| Q38011697 | Small molecule drug discovery at the glucagon-like peptide-1 receptor |
| Q36514704 | Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise |
| Q38033552 | The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus |
| Q38733474 | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions |
| Q82276828 | The market in diabetes |
| Q36839907 | The new diabetes inhalers: new tools for the clinician |
| Q88393664 | The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors |
| Q36643550 | The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. |
| Q35044628 | Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats |
| Q42181887 | Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury |
| Q60301930 | Treatment approach to type 2 diabetes: Past, present and future |
| Q26783350 | Treatment of prediabetes |
| Q38634679 | Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review |
| Q27694430 | Type 2 diabetes can be prevented with early pharmacological intervention |
| Q38241464 | What are the pharmacotherapy options for treating prediabetes? |
Search more.